Panbela Therapeutics, Inc. (PBLA) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 Waconia, MN, 美国. 现任CEO为 Jennifer K. Simpson.
PBLA 拥有 IPO日期为 2017-01-03, 7 名全职员工, 在 Other OTC, 市值为 $971.00.
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.
